Skip to main content
Premium Trial:

Request an Annual Quote

PreciseDx Partners With UCLA to Study Cancer Recurrence Risk Assay in TNBC

NEW YORK – PreciseDx and the University of California, Los Angeles' Department of Pathology and Laboratory Medicine on Tuesday announced a research collaboration to evaluate the ability of the company's PreciseBreast assay to assess risk of recurrence in triple-negative breast cancer patients.

The study is an expansion of an earlier validation study of PreciseBreast, which was conducted with Mount Sinai Hospital in New York. The new study will involve a large, well-annotated, outcome-based TNBC cohort from the UCLA Health System.

The research collaboration aims to confirm the efficacy and reliability of PreciseBreast. If further validated, the assay could improve early detection of TNBC recurrence and support personalized treatment strategies, according to PreciseDx.

"Risk assessment regarding the likelihood of disease recurrence is a critical first step in the phenotypic characterization of all cancer diagnoses, especially in aggressive subtypes like triple-negative breast cancer, which is often associated with poor patient outcomes because of the development of metastases in secondary organs, including the brain, bone, and lungs," Nicholas Stanzione, assistant clinical professor of pathology and laboratory medicine at UCLA, said in a statement.

PreciseBreast is an artificial intelligence-based assay that analyzes H&E stained tumor tissue images for certain elements of invasive cancer. The assay assigns a risk score to the samples to categorize a patient's risk of recurrence within six years of a definitive treatment.

New York-based PreciseDx is also developing an AI-based assay to predict recurrence risk using a patient's breast biopsy sample and a prostate cancer-focused test.